4.7 Review

Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review

Related references

Note: Only part of the references are listed.
Article Medicine, General & Internal

Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19 A Meta-analysis

Andrea B. Troxel et al.

Summary: This meta-analysis found no association of CCP with better clinical outcomes for the typical patient, and it provides a model for conducting real-time individual patient data pooling and meta-analysis during a pandemic.

JAMA NETWORK OPEN (2022)

Article Hematology

Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab

Barbora Bacova et al.

Summary: Patients treated with B-cell-targeting therapies have decreased serological response to SARS-CoV-2 mRNA vaccines, but the majority of these patients still develop sufficient cell-mediated immunity, suggesting that vaccination may be meaningful in terms of protection against SARS-CoV-2 infection.

HAEMATOLOGICA (2022)

Review Infectious Diseases

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Cathrine Axfors et al.

Summary: This study assessed the benefits of convalescent plasma treatment compared to placebo or no treatment in COVID-19 patients and found that convalescent plasma treatment did not reduce all-cause mortality. The researchers recommend that convalescent plasma treatment for COVID-19 patients should not be used outside of randomized trials. Collaboration among trial investigators can inform both evidence generation and evidence application in patient care.

BMC INFECTIOUS DISEASES (2021)

Article Medicine, General & Internal

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

R. Libster et al.

Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

V. A. Simonovich et al.

Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Review Immunology

Convalescent plasma may be a possible treatment for COVID-19: A systematic review

Ying Wang et al.

Summary: The effectiveness of convalescent plasma (CP) immunotherapy for COVID-19 in reducing mortality and improving clinical symptoms remains controversial based on current evidence, but it may have a positive impact on treating COVID-19 patients.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Review Medicine, General & Internal

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis

Stephen A. Klassen et al.

Summary: Studies show that COVID-19 convalescent plasma can lower mortality rates in patients, especially when administered early and with higher antibody titers.

MAYO CLINIC PROCEEDINGS (2021)

Review Virology

Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics

Jenifer Kiem Aviani et al.

Summary: CPT has shown potential benefits in treating COVID-19 and other viral respiratory diseases, with reduced mortality and increased number of discharged patients. Current studies suggest that CPT may act by rapidly reducing viral titers, but further large-scale randomized controlled studies are needed for validation.

REVIEWS IN MEDICAL VIROLOGY (2021)

Review Virology

Identification, Mechanism, and Treatment of Skin Lesions in COVID-19: A Review

Diego Fernandez-Lazaro et al.

Summary: COVID-19 is a multisystem disease primarily causing respiratory symptoms and associated with various cutaneous manifestations like vesicular eruptions, petechial/purpuric rashes, acral lesions, liveoid lesions, urticarial rash, and maculopapular-erythematous rash. Skin lesions may provide early signs of SARS-CoV-2 infection, and the presence of liveoid lesions could indicate a more severe disease course. Treatment options include anticoagulants, corticosteroids, and antihistamines for dermatologic manifestations. Knowledge of these skin manifestations aids in COVID-19 diagnosis and personalized care planning.

VIRUSES-BASEL (2021)

Article Education, Scientific Disciplines

Passive immune therapies: another tool against COVID-19

Lise J. Estcourt

Summary: Passive immune therapy, including convalescent plasma and monoclonal antibodies, is considered for severe COVID-19 cases, especially for high-risk patients, with vaccines being the primary prevention method. Regulatory approval has been granted for casirivimab/imdevimab cocktail in certain countries, while emergency use authorization applies to other treatments.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2021)

Review Medicine, General & Internal

Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic?

Diego Fernandez-Lazaro et al.

Summary: Long COVID (LC) is a multisystem illness caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), characterized by symptoms like fatigue and cognitive dysfunction. Patients may experience persistent symptoms for 4-12 weeks with no specific treatment currently available.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Anesthesiology

Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and meta-regression

Timothy A. C. Snow et al.

Summary: The study found that convalescent plasma treatment did not show a clear mortality benefit in COVID-19 patients, and it did not prevent the need for mechanical ventilation or ICU admission in patients with mild disease.

BRITISH JOURNAL OF ANAESTHESIA (2021)

Review Immunology

Glycophosphopeptical AM3 Food Supplement: A Potential Adjuvant in the Treatment and Vaccination of SARS-CoV-2

Diego Fernandez-Lazaro et al.

Summary: The world is currently facing the COVID-19 pandemic caused by SARS-CoV-2, with limited treatment options and slow vaccination rates. β-glucans, natural substrates with immunomodulatory activity, could potentially serve as an adjunct therapeutic agent for treating COVID-19 infections.

FRONTIERS IN IMMUNOLOGY (2021)

Article Immunology

Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV

Ping-Ing Lee et al.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION (2020)

Review Immunology

Convalescent plasma in Covid-19: Possible mechanisms of action

Manuel Rojas et al.

AUTOIMMUNITY REVIEWS (2020)

Editorial Material Medicine, General & Internal

Convalescent Plasma to Treat COVID-19 Possibilities and Challenges

John D. Roback et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Article Medicine, General & Internal

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Review Medicine, General & Internal

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review

James M. Sanders et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Review Medicine, Research & Experimental

Deployment of convalescent plasma for the prevention and treatment of COVID-19

Evan M. Bloch et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Article Multidisciplinary Sciences

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Kai Duan et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Review Virology

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Karthick Rajendran et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Review Infectious Diseases

Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks

Denise J. Wooding et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

Article Infectious Diseases

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies

Atul Sharma et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)

Article Medicine, General & Internal

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Michael J. Joyner et al.

MAYO CLINIC PROCEEDINGS (2020)

Article Biochemistry & Molecular Biology

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Sean T. H. Liu et al.

NATURE MEDICINE (2020)

Review Environmental Sciences

Physical Exercise as a Multimodal Tool for COVID-19: Could It Be Used as a Preventive Strategy?

Diego Fernandez-Lazaro et al.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)

Article Radiology, Nuclear Medicine & Medical Imaging

Convalescent plasma therapy in a pregnant COVID-19 patient with a dramatic clinical and imaging response: A case report

Ramezan Jafari et al.

WORLD JOURNAL OF RADIOLOGY (2020)

Article Biochemistry & Molecular Biology

Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19

Xiangyu Chen et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Article Hematology

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

O. Garraud et al.

TRANSFUSION CLINIQUE ET BIOLOGIQUE (2016)

Review Hematology

Adverse effects of plasma transfusion

Suchitra Pandey et al.

TRANSFUSION (2012)

Article Infectious Diseases

Use of convalescent plasma therapy in SARS patients in Hong Kong

Y Cheng et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)